UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/825,682	04/04/2001	Elena Feinstein	65503-B/JPW/MS	3555

7590 04/27/2005

John P. White
Cooper & Dunham LLP
1185 Avenue Of the Americas
New York, NY 10036

EXAMINER	
JOHANNSEN, DIANA B	
ART UNIT	**PAPER NUMBER**
1634	

DATE MAILED: 04/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

SUPPLEMENTAL EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

2. **Amend the specification as follows**:

Amend the specification as specified in the attached Amendment, which was requested by the examiner on March 2, 2005, and submitted to the examiner by facsimile on April 11, 2005.

3. It is noted that certain portions of the Amendment submitted April 11, 2005 are not in the format specified in MPEP 1302.04 for facsimile attachments to an examiner's amendment (specifically, 3 paragraphs provided by applicant are in a "marked-up" format, rather than a "clean" format). Accordingly, in the event that the "marked-up" versions are unusable for printing purposes, "clean" versions of the paragraphs submitted by Applicant are set forth below:

On page 55, lines 15 to 26:

--Many of the unexpected phenomena can indicate the limitation of previous understanding, and serve as a starting point for class definition. However, "outlying" hybridizations can also indicate quality problems. Overall, in each set (Figures 1-4) most of the separation between hybridizations is consistent with the expected TCC and normal urothelium separation. Even in hybridizations of lower quality, such as those of the second set, a clear separation between TCC and normal samples is observed.—

On page 55, lines 29 to 39:

--One of the TCC samples in the first set (TC6) is such an "outlyer" (Figure 1), as well as one of the normal samples in the second set, and another normal sample (TC35) in the third. (The "outlyers" do not appear to be misclassifications). For example, TC35 (a normal sample which is an "outlyer" in the third set) does not behave like a TCC sample. Rather those genes that are up-regulated in TCC samples are down-regulated in TC35).—

On page 59, lines 1 to 13:

--None of the "outlyers" was eliminated from subsequent analysis steps. Rather, they were included to facilitate the selection of a more robust marker set (Figures 1-4). Here, more complex relations are observed between global expression profiles. First, the two invasive hybridizations (TC34 and TC45), are distinct from other TCC samples (Figures 1-6). Second, the relationship between global Ta and T1 profiles is not straightforward.

Most of the Ta samples form a unique cluster in the 3rd set, while the T1 samples are more dispersed.—

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Diana B. Johannsen whose telephone number is 571/272-0744. The examiner can normally be reached on Monday-Friday, 7:30 am-4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached at 571/272-0745. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Diana B. Johannsen
Primary Examiner
Art Unit 1634
April 13, 2005

Attachment to the Supplemental Examiner's Amendment

Requested DNS 4/13/05

COOPER & DUNHAM LLP
ATTORNEYS AT LAW
1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036
TELEPHONE: (212) 278-0400

FACSIMILE TRANSMISSION

FACSIMILE: (212) 391-0525
(212) 391-0526
(212) 391-0630

OF COUNSEL
DONALD S. DOWDEN
PEDRO C. FERNANDEZ

FOUNDED 1887
www.cooperdunham.com

* NEW YORK STATE BAR ADMISSION PENDING

PLEASE DELIVER THE FOLLOWING PAGES

TO : D. Johannsen

COMPANY/FIRM : United States Patent and Trademark Office

FACSIMILE NO.: (571) 273-0744

FROM : John P. White/DNS

TOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 47

DATE : April 11, 2005 **TIME:**

IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (212) 278-0400.

DOCKET: 2094/65503-B **U.S. SERIAL NUMBER:** 09/825,682

MESSAGE: AMENDMENT AFTER PAYMENT OF ISSUE FEE IN RESPONSE TO MARCH 2, 2005 TELEPHONE REQUEST BY EXAMINER JOHANNSEN

Docket. No. 65503-B/JPW/DNS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elena Feinstein and Orna Mor

Serial No.: 09/825,682 Group Art Unit: 1634

Filed : April 4, 2001 Examiner: D. Johannsen

For : METHODS OF DIAGNOSING BLADDER CANCER

1185 Avenue of the Americas
New York, New York 10036
April 11, 2005

BY FACSIMILE - (571)273-0744
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FACSIMILE CERTIFICATION OF TRANSMISSION IN CONNECTION WITH THE ABOVE-IDENTIFIED APPLICATION

Date of Facsimile: April 11, 2005. I hereby certify that this paper including Amendment After Payment of Issue Fee in Response to March 2, 2005 Telephone Request By Examiner Johannsen is being transmitted to the **U.S. Patent and Trademark Office** on the date indicated above by facsimile and is addressed to **U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 Attn: D. Johannsen.**

Printed Name: Daniel Smith

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Docket No. 65503-B/JPW/DNS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elena Feinstein and Orna Mor

Serial No.: 09/825,682 Examiner: D. Johannsen

Filed : April 4, 2001 Group Art Unit: 1634

For : METHODS OF DIAGNOSING OF BLADDER CANCER

1185 Avenue of the Americas
New York, New York 10036
April 11, 2005

BY FACSIMILE - (571)-273-0744
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT AFTER PAYMENT OF ISSUE FEE IN RESPONSE TO MARCH 2, 2005 TELEPHONE REQUEST BY EXAMINER JOHANNSEN

This Amendment is submitted in response to a March 2, 2005 telephone request from Examiner Johannsen, communicated to Daniel N. Smith of the undersigned's office during which Examiner Johannsen requested amendments to the specification of the above-identified application. Accordingly, applicants submit this Amendment in response to the Examiner's request.

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 32 of this paper.

Amendments to the Specification

Please add the following section on page 8, line 5 of the specification immediately before the beginning of "DETAILED DESCRIPTION OF THE INVENTION":

-- **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1: This figure shows relationships between hybridizations' hierarchical clustering of Set #1 hybridizations. Either the Pearson correlation coefficient or a standard Euclidean distance was used as the distance measure between differential hybridization vectors. Hybridizations were clustered according to these distances by average linkage hierarchical clustering. Missing values were deleted on a case-wise basis. Clusters of Missing values hybridizations can be identified and evaluated in light of existing knowledge.

Figure 2: This figure shows relationships between hybridizations' hierarchical clustering of Set #2 hybridizations. Either the Pearson correlation coefficient or a standard Euclidean distance was used as the distance measure between differential hybridization vectors. Hybridizations were clustered according to these distances by average linkage hierarchical clustering. Missing values were deleted on a case-wise basis. Clusters of Missing values hybridizations can be identified and evaluated in light of existing knowledge.

Figure 3: This figure shows relationships between hybridizations' hierarchical clustering of Set #3 hybridizations. The figure is a tree diagram for 21 variables with unweighted pair-group average. The Pearson correlation coefficient was used as the distance measure between differential hybridization vectors. Hybridizations

were clustered according to these distances by average linkage hierarchical clustering. Missing values were deleted on a case-wise basis. Clusters of Missing values hybridizations can be identified and evaluated in light of existing knowledge.

Figure 4: This figure shows relationships between hybridizations' hierarchical clustering of Set #3 hybridizations. The figure is a tree diagram for 21 variables with unweighted pair-group average. The standard Euclidean distance was used as the distance measure between differential hybridization vectors. Hybridizations were clustered according to these distances by average linkage hierarchical clustering. Missing values were deleted on a case-wise basis. Clusters of Missing values hybridizations can be identified and evaluated in light of existing knowledge.

Figure 5: This figure shows relationships between hybridizations' hierarchical clustering for all TCC sample hybridizations. The figure includes raw data with unweighted pair-group average. The Pearson correlation coefficient was used as the distance measure between differential hybridization vectors. Hybridizations were clustered according to these distances by average linkage hierarchical clustering. Missing values were deleted on a case-wise basis. Clusters of Missing values hybridizations can be identified and evaluated in light of existing knowledge.

Figure 6: This figure shows relationships between hybridizations' hierarchical clustering for all TCC sample hybridizations. The figure includes raw data with unweighted pair-group average. The standard Euclidean distance was used as the distance measure between

differential hybridization vectors. Hybridizations were clustered according to these distances by average linkage hierarchical clustering. Missing values were deleted on a case-wise basis. Clusters of Missing values hybridizations can be identified and evaluated in light of existing knowledge.--

Please amend the paragraph on page 55, lines 15 to 26 of the specification as follows:

--Many of the unexpected phenomena can indicate the limitation of previous understanding, and serve as a starting point for class definition. However, "outlying" hybridizations can also indicate quality problems. Overall, in each set ~~(Table B3)~~ (Figures 1-4) most of the separation between hybridizations is consistent with the expected TCC and normal urothelium separation. Even in hybridizations of lower quality, such as those of the second set, a clear separation between TCC and normal samples is observed.--

Please amend the paragraph beginning on page 55, lines 29 to 39 of the specification as follows:

--One of the TCC samples in the first set (TC6) is such an "outlyer" ~~(Table B3)~~ (Figure 1), as well as one of the normal samples in the second set, and another normal sample (TC35) in the third. (The "outlyers" do not appear to be misclassifications). For example, TC35 (a normal sample which is an "outlyer" in the third set) does not behave like a TCC sample. Rather those genes that are up-regulated in TCC samples are down-regulated in TC35).--

Please delete pages 56 to 58 of the specification.

Please amend the paragraph beginning on page 59, lines 1 to 13 of the specification as follows:

-- None of the "outlyers" was eliminated from subsequent analysis steps. Rather, they were included to facilitate the selection of a more robust marker set ~~(Table B3)~~ (Figures 1-4). Here, more complex relations are observed between global expression profiles. First, the two invasive hybridizations (TC34 and TC45), are distinct from other TCC samples ~~(Tables B3 and B4)~~ (Figures 1-6). Second, the relationship between global Ta and T1 profiles is not straightforward. Most of the Ta samples form a unique cluster in the 3rd set, while the T1 samples are more dispersed.--

Please renumber pages 59 to 82 of the specification as pages 56 to 79.

Please replace the existing Table E on pages 83 and 84 of the specification with the following new Table E expanded into 8 pages to improve legibility:

--

TABLE E (Page 1)

Index	GeneDescription1
1	Human 54 kDa protein mRNA, complete cds ; nt_non_genomic(identity) REPEAT:contig_ICC_2966_RF.fa
2	none:11_TCC_74D3_1_M13F.fa none:25_TCC_74D3_1_M13R.fa (AL121586) dJ477O4.1 (novel protein similar to otoferlin and dysferlin) (Homo sapiens) ;
3	nt(identity):10_ICC_70E2_1_M13F.fa Homo sapiens serine protease inhibitor, Kunitz type, 2 (SPINT2), mRNA ; nt_non_genomic(identity):24_TCC_70E2_1_M13R.fa
4	Homo sapiens full length insert cDNA clone ZC48G12 ; nt_non_genomic(identity):contig_ICC_7587_RF.fa
5	Homo sapiens GPI-anchored metastasis-associated protein homolog (C4.4A), mRNA ; nt_non_genomic(identity):contig_ICC_8915_RF.fa
6	Homo sapiens cDNA: FLJ22720 fis, clone HSI1432D nt_non_genomic(identity):16_TCC_101D4_1_M13F.fa ANKHZN protein (Homo sapiens)300.1	(AB037360) ANKHZN (Homo sapiens) ; nt(identity):30_TCC_101D4_1_M13R.fa
7	low molecular mass ubiquinone-binding protein (Homo sapiens)	UCRQ_HUMAN UBIQUINOL-CYTOCHROME C (REDUC ; nt(identity):contig_ICC_67C11_RF.fa none:14_TCC_7981_1_M13F.fa Homo sapiens quiescin Q6 (QSCN6), mRNA ;
8	nt_non_genomic(identity):28_TCC_7981_1_M13R.fa Homo sapiens mRNA; cDNA DKFZp564C2282 (from clone DKFZp564C2282) ;
9	nt_non_genomic(identity):contig_TCC_74H12_RF.fa
10	Homo sapiens full length insert cDNA clone ZC48G12 ; nt_non_genomic(identity):contig_ICC_5661_RF.fa
11	NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2 (14.5kD, B14.5b) (Homo sapiens)	N4BM_HUMAN ;
12	nt(identity):contig_TCC_60B2_RF.fa
13	
14	

TABLE E (Page 2)

Acc	GeneID	TC7A_BDE_DIFF	TC8A_BDE_DIFF	TC9A_BDE_DIFF	TC10A_BDE_DIFF
gi|407307|gb|U02493.1|HSU02493	TCC-29E_6	-1	-1.2	1.1	1
	TCC-74D_3	-1.1	-1	1.2	-1.1
gi|7671662|emb|CAB89410.1|	TCC-70E_2	-1.2	1.1	1.2	-1.1
gi|10863908|ref|NM_021102.1|					
gi|3483555|gb|AF086210.1|HUMZC48G12	TCC-75B_7	-1.1	1	1.2	-1.2
gi|7656943|ref|NM_014400.1|	TCC-89H_5	-1.1	-1	1.1	1
gi|10439219|dbj|AK026373.1|AK026373					
gi|7705278|ref|NP_057460.1|	TCC-101D_4	-1.1	-1.1	1.1	-1.1
gi|7657486|ref|NP_055217.1|	TCC-67C_11	1	-1.1	-1	1
gi|4506360|ref|NM_002826.1|	TCC-79B_1	-1.1	1	1.2	-1.1
gi|7328021|emb|AL161965.1|HSM802543	TCC-74H_12	-1.1	-1.1	1.3	-1.1
gi|3483555|gb|AF086210.1|HUMZC48G12	TCC-56G_1	-1	-1	1.3	-1.1
	TCC-47D_9	1.1	1+	-1	-1.1
gi|4758784|ref|NP_004540.1|	TCC-60B_2	-1	1*	-1.1	-1.1
	TCC-23D_4	1.1		-1.2	1.2
	TCC-20F_5	-1.2	1.1	1.2	-1.2

TABLE E (Page 3)

TC11A_BDE_DIFF	TC22A_BDE_DIFF	TC21A_BDE_DIFF	TC23A_BDE_DIFF	TC24A_BDE_DIFF	TC47A_BDE_DIFF	TC36A_BDE_DIFF
1.2	-1.1	1.3	-1.2	1+	-1	1.1
-1	1.1	1	1	-1.2	1	-1
-1.1	1.2	1.1	1	-1.4	1.2	-1
-1	1.1	-1	1	-1.2	1.1	1
-1	1.2	-1	1.1	-1.2	1.1	1
1.2	1.1	1.1	1.1	-1.3	1.1	-1.1
1.1	1.1	1.1	-1	-1.2	-1	-1
-1	1.1	-1	1.1	-1.2	1.1	-1
1	1.2	1.2	-1	-1.4	1.1	-1.3
-1.1	1.2	1	1	-1.2	-1	1.1
-1	-1.3	1.4	-1.1	1+	-1.1	-1
1.3	-1	1.2	-1.1	1+	1.1	-1.2
1.3	-1.2	1.1	1.1	1+	-1.1	1.1
1.1	1.1	1	1.1	-1.2	1	-1.2

TABLE E (Page 4)

TC38A_BDE_DIFF	TC46A_BDE_DIFF	TC48A_BDE_DIFF	TC37A_BDE_DIFF	TC35A_BDE_DIFF	TC2A_BDE_DIFF	TC3A_BDE_DIFF
-1.1	1.1	1.4	-1	-1.5	1.1	-1.2
1.3	1.3	1.1	-1	-1.8	-1.5	-1.1
1.3	1.3	1.2	-1.1	-2.1	-1.3	-1.5
1.3	1.3	1.1	-1	-1.9	-1.3	-1.1
1.2	1.3	1.1	-1.1	-1.7	-1.2	-1.1
1.2	1.1	1	-1.2	-1.2	-1.4	1.1
1.2	1.3	1.1	-1	-1.8	-1.2	-1
1.3	1.3	1.2	-1.1	-1.6	-1.2	-1.3
1.3	1.3	1.1	-1.1	-1.8	-1.4	-1
-1.1	1.2	1.3	1.2	-1.7	-1.2	-1.2
-1.1	1.3	1.1	-1.1	-1.2	1	1.2
-1	1.1	1.3	1.1	-1.7	-1.1	-1.2
1.1	1.1	1.1	-1	-1.3	-1	1

TABLE E (Page 5)

TC4A_BDE_DIFF	TC5A_BDE_DIFF	TC8A_BDE_DIFF	TC16A_BDE_DIFF	TC17A_BDE_DIFF	TC18A_BDE_DIFF	TC25A_BDE_DIFF
1.4	1.2	-1.1	-1	-1.5	-1	1.4
1	1.5	1.1	1	1.3	1.5	1.5
-1.3	1.3	-1	1.2	1.5	1.3	1.4
-1.4	1.3	1.3	1.1	1.4	1.3	1.5
-1.3	1.2	1	1.1	1.5	1.1	1.5
-1.5	-1	-1	1	1.4	1.7	1.5
1.1	-1	-1	1.1	1.5	1.5	1.5
1.1	-1.2	1	1	1.4	1.4	1.5
-1.1	1.1	-1.2	1.1	1.4	1.4	1.5
-1.4	1.3	1.2	1.1	1.4	1.5	1.5
-1.6	1.2	-1	1.1	-1.3	1	1.3
-1.2	1	1	1.4	1.2	1.3	1.5
-2	1.4	1.1	-1.4	-1.5	-1.3	1.2
-1.2	-1.1	-1.1	-1.2	1.2	1.4	1.3

TABLE E (Page 6)

TC19A_BDE_DIFF	TC20A_BDE_DIFF	TC32A_BDE_DIFF	TC33A_BDE_DIFF	TC41A_BDE_DIFF	TC42A_BDE_DIFF	TC44A_BDE_DIFF
1.1	1.4	-1.4	-1.1	-1.1	-1.3	-1.3
1.1	1.3	-1.2	1.1	1.1	1.1	1.2
1.2	1.3	-1.3	-1.2	1.2	-1	1.2
1.4	1.1	-1.1	-1	1.1	1.1	1.1
1.4	1.1	-1.1	-1	1.1	1	-1.1
12	1.3	-1.3	-1.2	1.1	-1.1	-1
1.4	1.4	-1.3	-1.3	1.1	-1	-1
1.4	1.1	-1.1	1	1.1	-1	1.1
1.2	1.4	-1.5	-1.4	1.1	-1.1	1.2
1.4	1.3	-1.1	1	1.2	1	1.1
1.3	1.2	-1.5	-1.2	-1.2	-1.3	-1.3
1.2	1.2	-1.3	-1.2	-1.1	-1.4	-1.2
-1	-1.1	-1	-1.1	1	-1.3	-1.1
1.4	1.1	-1.2	-1.5	-1	-1.2	-1.3

TABLE E (Page 7)

TC31A_BDE_DIFF	TC39A_BDE_DIFF	TC43A_BDE_DIFF	TC40A_BDE_DIFF	TC30A_BDE_DIFF	TC28A_BDE_DIFF	TC29A_BDE_DIFF
-1.1	-1.2	-1.3	-1.3	-1.3	1.2	1.2
-1.3	-1.1	-1.4	-1.2	1.1	-1.1	1.2
-1.3	-1.1	-1.4	-1.2	1.1	-1.1	1.1
-1.3	-1.1	-1.5	-1.3	1.1	-1	1.1
-1.2	-1.2	-1.5	-1.2	1.1	-1.1	1.1
-1.3	-1.2	-1.4	-1.4	1.1	-1.3	-1.1
-1.4	-1.2	-1.4	-1.5	-1	-1.1	-1
-1.1	-1.1	-1.4	-1.3	1.1	-1.1	1.2
-1.3	-1.2	-1.5	-1.4	1.2	-1.1	1
-1.3	-1.1	-1.5	-1.3	1	-1.1	1.1
-1	-1.4	-1.5	-1.4	-1.5	1.1	1.2
-1.2	-1.8	-1.4	-1.3	-1.3	-1.1	-1.2
1.2	-1.3	1	-1.1	-1.2	1.4	1.4
-1.3	1	-1.2	-1	-1.3	1.1	-1.2

TABLE E (Page 8)

TC34A_BDE_DIFF	TC45A_BDE_DIFF
1.1	1.1
1.4	1.1
1.3	1.2
1.2	1.1
1.1	1.1
-1.1	-1
1.4	1.1
1.3	1.3
1.1	-1.1
1.2	1.1
1.3	-1.1
-1.2	1.2

--

Please replace the existing Table 1 on pages 85 and 86 of the specification with the following new Table 1 expanded into 8 pages to improve legibility:

--

TABLE 1 (Page 1)

	GeneDescription and clone ID
1	Homo sapiens keratin 19 (KRT19) gene, complete cd ; nt_non_genomic(identity):47_TCC_91B11_M13F.TXT.fa
2	Human 40-kDa keratin intermediate filament precur ; nt_non_genomic(identity):20_TCC_60H4_M13F.TXT.fa
3	Human mRNA fragment for mesothelial type II kerat ; nt_non_genomic(identity):04_TCC_94G3_M13F.TXT.fa
4	Homo sapiens cystatin B (CSTB) gene, promoter reg ; nt_non_genomic(identity):30_TCC_76B3_M13F_F04_042.ab1.TXT
5	Homo sapiens S100 calcium-binding protein P (S100P ; nt_non_genomic(identity):29_TCC_48G1_M13F.TXT.fa
6	Homo sapiens syndecan 1 (SDC1) mRNA ; nt_non_genomic(identity):26_TCC_75E3_M13F_804_092.ab1.TXT
7	Homo sapiens S100 calcium-binding protein A13 (S10 ; nt_non_genomic(identity):28_TCC_44C1_M13F.TXT.fa
8	Homo sapiens mRNA for hepatocyte growth factor ac ; nt_non_genomic(identity):35_TCC_21D8_M13F_C05_037.ab1.fa
9	Homo sapiens midkine (neurite growth-promoting fac ; nt_non_genomic(identity):32_TCC_89G3_M13F_811_092.ab1.TXT
10	Homo sapiens solute carrier family 2 (facilitated ; nt_non_genomic(identity):07_TCC_57B3_M13F.TXT
11	Homo sapiens S100 calcium-binding protein A11 (cal ; nt_non_genomic(identity):31_TCC_65B8_M13F.TXT.fa
12	Homo sapiens fatty acid binding protein 5 (psorias ; nt_non_genomic(identity):11_TCC_25F2_M13F.TXT
13	Homo sapiens Opa-interacting protein OIP3 mRNA, p ; nt_non_genomic(identity):38_TCC_56E11_M13F.TXT
14	Homo sapiens glutaminyl-tRNA synthetase (QARS), m ; nt_non_genomic(identity):46_TCC_78B11_M13F_F06_059.ab1.TXT
15	Homo sapiens anterior gradient 2 (Xenopus laevis) ; nt_non_genomic(identity):25_TCC_50G5_M13F.TXT
16	Homo sapiens myristoylated alanine-rich protein k ; nt_non_genomic(identity):10_TCC_53H11_T3
17	Homo sapiens leukemia-associated phosphoprotein p1 ; nt_non_genomic(identity):46_TCC_27H5_M13F_F06_058.ab1.fa
18	Homo sapiens type II membrane serine protease (LO ; nt_non_genomic(identity):53_TCC_79G2_M13_FE07_054.ab1.TXT
19	Homo sapiens putative secreted protein XAG mRNA, c ; nt_non_genomic(identity):26_TCC_50G8_M13F.TXT
20	H.sapiens (xscad) mRNA, 3400bp ; nt_non_genomic(identity):40_TCC_13F11_M13F.fa

TABLE 1 (Page 2)

		T1	G2/3	G2/3
		T1	T1	T1
Accession	GeneID	TC2A_BDE_DIFF	TC3A_BDE_DIFF	TC4A_BDE_DIFF
gi|6729660|gb|AF202321.1|AF202321	TCC-91B_11	3.7	3	5.4
gi|1846581|gb|U03607.1|HUMIFP	TCC-60H_4	3.7	2.7	5.9
gi|34067|emb|X03212.1|HSKER7R	TCC-94G_3	3.3	2.7	6.3
gi|7263011|gb|AF208234.1|AF208234	TCC-76B_3	5.7	2.2	3
gi|5174662|ref|NM_005980.1|	TCC-48G_1	2.7	4.8	8.9
gi|4506858|ref|NM_002997.1|	TCC-75E_3	1.9	2.6	2.5
gi|5174658|ref|NM_005979.1|	TCC-44C_1	3.1	4.8	9.3
gi|29246819|dbj|AB006534.1|AB006534	TCC-21D_6	1.1	1.1	-2.2
gi|4505134|ref|NM_002391.1|	TCC-89G_3	2.2	1.7	3.7
gi|5730050|ref|NM_006516.1|	TCC-57B_3	4.8	1.2	2.2
gi|5032056|ref|NM_005620.1|	TCC-65B_9	3.5	2	3.4
gi|4557580|ref|NM_001444.1|	TCC-25F_2	2.1	2.3	1.1
gi|2815605|gb|AF025439.1|AF025439	TCC-56E_11	3.4	2.1	2.4
gi|4826959|ref|NM_005051.1|	TCC-78B_11	2.2	2.8	5.3
gi|5453540|ref|NM_008408.1|	TCC-50G_5	2.4	5.8	3.4
gi|4505082|ref|NM_002356.1|	TCC-53H_11	1.6	1	-1.6
gi|5031850|ref|NM_005563.1|	TCC-27H_5	1.8	1.7	2
gi|7705976|ref|NM_016425.1|	TCC-79G_2	5.6	2.6	7.2
gi|6652811|gb|AF088867.1|AF088867	TCC-50G_6	2.3	5.7	3.6
gi|533966|emb|Z36852.1|HSXSCAD	TCC-13F_11	-1.2	-1.1	-2

TABLE 1 (Page 3)

G2/3	G1/2						
T1	T1	normal	normal	normal	normal	normal	
TC5A_BDE_DIFF	TC8A_BDE_DIFF	TC7A_BDE_DIFF	TC8A_BDE_DIFF	TC9A_BDE_DIFF	TC10A_BDE_DIFF	TC11A	
1.5	3.1	1	-2.5	-2	1.2	-1.2	
1.5	2.9	1	-2.6	-1.9	1.3	-1.1	
3.1	1.6	1	-2.1	-1.8	1.3	-1.4	
1.6	1.3	1	-2	-1.8	-1	-1.2	
1.7	1.7	1	-2.6	-2.5	2.1	1.6	
1	1.6	1	-1.7	-1.3	-1.1	-1.5	
1.6	1.6	1	-2.6	-2.4	1.9	1.4	
2	1.8	1	-1.6	-1.2	1.1	-1.5	
-1.5	1.9	1	-1.2	1.2	-1.8	-1.2	
1.2	3.2	1	-2.1	-1.5	1.1	-1.6	
1.5	1.6	1	-1.4	-1.7	1.1	-1.1	
2.6	5	1	-1.5	-1.5	2	1	
1.1	1.6	1	-1.1	-1.1	-1.3	1.1	
1.6	1.6	1	-1.1	-1.3	1.1	1.1	
-1.2	1.2	1	-2	-1.9	1.5	1.2	
1.6	1.7	1	-1.3	1.3	1.6	1.1	
2.2	1.6	1	-1.2	1.2	-1.1	1.1	
-1.6	-1.2	1	-2.2	-2.1	1.1	-1.2	
-1.1	1.3	1	-1.8	-1.9	1.4	1.2	
1.8	1.6	1	-1.6	-1.3	-1	-1.5	

TABLE 1 (Page 4)

G2		G2		High		Low		G3	
T1		Ta		Ta		T1		T1	normal
TC16A_BDE_DIFF		TC17A_BDE_DIFF		TC18A_BDE_DIFF		TC19A_BDE_DIFF		TC20A_BDE_DIFF	TC21A_BDE_DIFF
2.6		2.4		2.5		2.6		1.7	-1.3
2.4		2.6		3.6		2.9		1.8	-1.2
7.1		4.6		6.3		4.1		4.3	-1.6
3.6		11		6.9		2.3		3.4	-1.5
3		6.1		8.2		2.8		1.3	1.3
5		4.6		4		2.4		4.7	-1.3
2.8		4.9		6.8		2.5		1.1	-1.1
2.7		2.6		2.6		1.7		2	1.2
1.9		2.5		1.9		1.4		2.9	1.1
2.7		1.8		2.9		-1		1.4	-1.2
2.9		3.8		2.7		2.3		1.5	-1.8
1.2		1.7		4.6		2.2		1.6	-2.5
2.8		3.6		4.5		2.3		1.7	1.1
2.7		5		2.1		1.9		1.8	-1.6
2.8		2.8		2.9		4.9		1.6	-1.4
1.9		1.6		2.5		1.5		2.2	-2.1
-1.1		-1.4		1.4		-1.4		1.2	-1.3
3.8		1.4		3.6		3.9		-1.2	1.3
3.1		3.7		4.5		4.4		2.1	-1.3
1.8		2.1		2.2		1.2		1.8	-1.3

TABLE 1 (Page 5)

normal		normal		Low	G3	High	G3
				T1	T1+TIS	T1	T1
TC22A_BDE_DIFF	TC23A_BDE_DIFF	TC24A_BDE_DIFF		TC25A	TC28A_BDE_DIFF	TC29A_BDE_DIFF	TC30A_BDE_DIFF
1	1.3	-2.1		2.6	2.4	2.2	2
1	1.2	-1.9		2.1	2.2	2	1.8
1	1.8	-1.7		4	1.5	3.5	3.6
1	1.7	-1.8		4.4	-1.3	2	2.1
1	1.9	-1.1		4.4	-1.1	3.5	3.2
1	1.4	-1.1		2.7	1.6	1.2	1.3
1	1.9	-1.1		3.5	1.2	2.4	2
1	1.5	1.7		2.4	3.9	2.2	1.7
1	1.4	1		3.7	7	2	-1.1
1	1.2	-1.2		2.4	-1.1	2	2.7
1	1.2	-2.4		3.8	-1.1	2.4	1.1
1	1.1	1		1.8	-1.8	1	5.7
1	1.4	-1.2		3.1	-1.3	1.2	1.1
1	1.2	-2		2.4	1.1	1.7	1.3
1	1.2	1.4		3.1	-1.3	1.8	1.2
1	1.1	-2.3		3.9	-1.3	2.5	2
1	1.1	1.6		-1.3	5.7	6.7	1.9
1	2.1	1.4		3.8	-2.1	-1.5	1.5
1	1.5	1.2		3.7	-1.5	1.5	-1
1	-1.1	-1.3		1.8	4.6	2.8	1.9

TABLE 1 (Page 6)

G1/2	G2	G2	INV		
Ta	Ta/T1	Ta		normal	normal
TC31A_BDE_DIFF	TC32A_BDE_DIFF	TC33A_BDE_DIFF	TC34A_BDE_DIFF	TC35A_BDE_DIFF	TC36A_BDE_DIFF
2.1	2.3	2.4	-1	-3.9	-1.4
1.8	2	1.9	-1.2	-4.5	-1.6
4.3	3.2	2.1	1.1	-3.3	-1.2
1.6	4.8	2	3.3	-1.4	-1
3.7	5	2.6	1.8	-4	1
4.3	3.7	2.2	1.1	1.1	-1
2.4	3.1	1.7	1.6	1.2	1
2.5	2.6	2.7	2.1	2	-1.3
2.5	1.8	2.5	1.3	-1.3	1.1
13	1.8	3.8	3	1.4	1.1
2.3	2.4	1.8	2.5	-1.5	-1.2
3.5	1	3.9	-1.1	-4.1	-1.5
3.1	1.6	1.8	-1.1	2	-1.2
-1	2	1.9	-1.1	-2.3	-1.4
2.3	6.7	-1.3	1.3	-1.3	1.2
3.7	2.6	2.5	-2.1	-1.2	1.1
1.8	1	1.7	3.5	1.5	1.3
5.3	-1.9	3.2	-1.8	-1.8	-1.2
2.1	6	-1.5	1.1	-1.3	-1.1
3	3.1	3.1	2.5	2.4	-1.1

TABLE 1 (Page 7)

		Low		G2/3		G2		G2
normal		Ta		T1		Ta		Ta
TC37A_BDE_DIFF	TC38A_BDE_DIFF	TC39A_BDE_DIFF		TC40A_BDE_DIFF		TC41A_BDE_DIFF		TC42A_BDE_DIFF
-1.8	-1.4	3.2		3.1		2.2		2.6
-2.3	-1.8	2.9		2.5		1.8		2.4
-1.4	-1.3	3.5		1.9		2.4		2.5
-1.6	-1	4.1		2.3		1.7		1.5
-1.7	-1.3	3.4		4.5		1.3		3.3
-1	1	2.3		3.4		2		1.9
-1.6	-1	2.4		2.7		1.1		2.4
-1.8	1	1.4		1.6		2.6		1.6
1.2	1	1.8		4		1.7		2.5
1.4	1.1	3.8		3.4		3.2		1.4
-1.8	-1.1	2.7		1.2		2.1		1.9
-1.9	-1.1	1.1		2.8		2.5		2
-1.4	-1	2.3		2		1.8		1.9
-1.6	-1.3	1.6		2.6		1.1		1.3
1.3	1.1	1.9		1.5		1.9		2.5
-1.2	1.1	1.3		1.6		2		1.4
1.2	1.1	1.9		2.5		2.4		1.7
-1.1	-1.1	2.2		1.5		2.3		2.8
1	1	1.6		1.2		1.9		2.3
-1.7	1.2	1.7		1.9		2.9		2

TABLE 1 (Page 8)

G2	G2						
T1	Ta	INV	normal	normal	normal		
TC43A_BDE_DIFF	TC44A_BDE_DIFF	TC45A_BDE_DIFF	TC46A_BDE_DIFF	TC47A_BDE_DIFF	TC48A_BDE_DIFF	secreted	
1.7	3.6	1.1	-1	1	-1.1	3.9	
1.6	3.6	1.1	-1.1	1	-1.1	3.8	
1.8	5.6	-1.3	-1.1	1	-1.2	3.8	
2.2	3.3	1.2	1.1	1	-1.1	-1.8	
2.3	3.4	-1.6	-1.2	1	-1	-1.2	
2.2	3.1	1.1	-1	1	-1.1	1	
1.5	2.9	-1.4	1.1	1	-1	-1.4	
2	3	1.2	-1.1	1	-1.3	-2.2	
1.4	2.3	1.5	1.9	1	1.1	-2.6	
2.6	3.8	2.7	1.1	1	1		
1.2	3.1	1.3	1.1	1	-1.3	-1.6	
2.2	3.9	2.1	1.1	1	-1.2	-1.2	
1.3	2.8	1.4	1	1	-1.2	4.9	
1.3	1.4	-1.3	1.1	1	-1.1	-1.5	
1.8	2.3	1.1	-1.4	1	-1.2		
2	1.3	1.4	1.6	1	-1.1	3.8	
1.4	1	2.5	1	1	1	1.9	
2.8	3.1	1.1	-1.2	1	-1.2	-1.7	
1.9	2.9	1.1	-1.3	1	-1.1	-1.4	
2.1	3.2	1.3	1	1	-1.2	-2.2	

Applicants: Elena Feinstein and Orna Mor
Serial No.: 09/825,682
Filed: April 4, 2001
Page 22

Please replace the existing Table 2 on pages 87 and 88 of the specification with the following new Table 2 expanded into 10 pages to improve legibility:

--

TABLE 2 (Page 1)

		GeneDescription and clone ID
1		Homo sapiens full length insert cDNA clone ZC48G12 ; nt_non_genomic(identity):03_TCC_57E11_T7.TXT.fa
2		xq01h07.x1 Soares_NHCeC_cervical_tumor Homo sapien ; est(identity):24_TCC_9BC7_M13F.TXT
3		hh68c04.x1 NCI_CGAP_GU1 Homo sapiens cDNA clone IM ; est(identity):26_TCC_13H10_M13F_B04_032.ab1.fa
4		none:21_TCC_43E2_M13F.TXT
5		RC3-BN0053-170200-011-e12 BN0053 Homo sapiens cDNA ; est(identity):28_TCC_16D12_M13F_D04_041.ab1.fa
6		none:08_TCC_70E7_M13F_H01_015.ab1.TXT
7		Homo sapiens clone RP4-584D14, complete sequence ; nt_non_genomic(identity):14_TCC_9B6_M13F_F02_026.ab1.fa
8		Homo sapiens CGI-81 protein (LOC51108), mRNA ; nt_non_genomic(identity):11_TCC_101E11_M13F.TXT.fa
9		Homo sapiens mRNA for KIAA0660 protein, complete ; nt_non_genomic(identity):72_TCC_37E11_M13F_H09_079.ab1.fa
10		H.sapiens GalNAc-T1 gene, 3'UTR ; nt_non_genomic(identity):54_TCC_30E5_M13F_F07_062.ab1.fa
11		none:15_TCC_71H8_M13F_G02_019.ab1.TXT
12		Homo sapiens ETAA16 protein (ETAA16), mRNA ; nt_non_genomic(identity):09_TCC_101C11_M13F.TXT.fa
13		Homo sapiens cDNA FLJ10861 fis, clone NT2RP4001S7 ; nt_non_genomic(identity):24_TCC_12F3_M13F_H03_031.ab1.fa
14		hh75c10.x1 NCI_CGAP_GU1 Homo sapiens cDNA clone IM ; est(identity):59_TCC_34D5_M13F_C08_065.ab1.fa
15		none:15_TCC_57C3_M13F.TXT.fa
16		yi81a11.r1 Soares breast 2NbHBst Homo sapiens cDNA ; est(identity):29_TCC_17A5_M13F_E04_034.ab1.fa
17		hypothetical protein C50F7.2 - Caenorhabditis eleg ; CONTIG_nr(strong):31_TCC_10E8_M13F.fa
18		none:13_TCC_71E4_M13F_E02_018.ab1.TXT
19		Homo sapiens mRNA; cDNA DKFZp434L0310 (from clone ; nt_non_genomic(identity):57_TCC_80C9_M13F_A08_056.ab1.TXT
20		none:44_TCC_70E8_M13F.TXT.fa

TABLE 2 (Page 2)

			T1	G2/3
Accession	GeneID	T1	TC2A_BDE_DIFF	TC3A_BDE_DIFF
gi|3483555|gb|AF086210.1|HUMZC48G12	TCC-57E_11		3.3	2.8
gi|7154678|gb|AW516596.1|AW516596	TCC-96C_7		2.8	4.3
gi|7318401|gb|AW613215.1|AW613215	TCC-13H_10		2.2	1.6
gi|8257938|gb|AW997704.1|AW997704	TCC-43E_2		2.7	4.7
	TCC-16D_12		2.7	5.3
gi|8468933|gb|AC005586.2|AC005586	TCC-70E_7		3.8	2.1
	TCC-9B_6		11	-1
gi|7705788|ref|NM_016025.1|	TCC-101E_11		5.1	2.1
gi|3327133|db|AB014560.1|AB014560	TCC-37E_11		8	-1.5
gi|2292903|emb|Y10343.1|HSY10343	TCC-30E_5		3.3	2.3
	TCC-71H_8		1.7	1.4
gi|9506580|ref|NM_019002.1|	TCC-101C_11		6.1	2.2
gi|7023162|dbj|AK001723.1|AK001723	TCC-12F_3		1.4	2
gi|7318796|gb|AW613610.1|AW613610	TCC-34D_5		1.6	2.5
	TCC-57C_3		3.5	2.8
gi|843837|gb|R70320.1|R70320	TCC-17A_5		2.7	2.6
gi|749778|pir||T29299	TCC-10E_8		1.1	1.4
	TCC-71E_4		1.7	1.6
gi|6808331|emb|AL137591.1|HSM802346	TCC-80C_9		3.7	2
	TCC-70E_8		4.1	2.2

TABLE 2 (Page 3)

G2/3		G2/3		G1/2				
T1		T1		T1		normal		normal
TC4A_BDE_DIFF		TC5A_BDE_DIFF		TC6A_BDE_DIFF		TC7A_BDE_DIFF		TC8A_BDE_DIFF
3.2		1.3		2.3		1		-1.3
5.8		5.9		-1.4		1		-1.3
2.1		1		1.2		1		-1.4
7.3		1.5		1.7		1		2.3
2.4		8.8		-1.4		1		2.7
3.6		1.6		1.5		1		-1.6
3.9		4.1		-1.6		1		-1.6
3.1		1.6		1.3		1		-1.5
3.1		3.1		-1.3		1		-1
-1.2		1.3		2		1		1.5
-1		2.5		2		1		-1.5
3.2		1.9		1.2		1		-2.3
1.1		-1.3		1.6		1		-1
1.9		1.1		1.4		1		1.1
2.9		1.2		2.3		1		-1.1
1.9		1.7		9.3		1		1.2
1.6		1.5		-1.1		1		1.3
1.3		2.3		2.1		1		-1.4
3.2		1.7		1.3		1		-1.5
3.7		1.7		1.5		1		1.3

TABLE 2 (Page 4)

	normal	normal	normal	G2	G2	High					
	TC9A_BDE_DIFF	TC10A_BDE_DIFF	TC11A	T1	Ta	Ta					
				TC16A_BDE_DIFF	TC17A_BDE_DIFF	TC18A_BDE_DIFF					
	-1.5	1.2	-1.2	2.2	2.6	3.7					
	-1	2.7	1.2	4	7.5	2.2					
	1.1	1	-1	1.3	1.2	1.3					
	-2.3	2.1	1.7	1.8	5.1	6.2					
	1.3	1.3	-1.2	3.6	4.4	-1.1					
	-2.1	1.1	-1.1	3.5	4.8	2.9					
	1	-1.2	-1.4	3	3.7	1.3					
	-1.4	1.1	1.2	2.8	7.2	4.4					
	-1.2	-1.4	-1.6	1.6	2	-1					
	1.1	1.8	2.1	-1.1	1.7	1.7					
	-1.2	1.1	-1.3	2.1	2.6	3					
	-1.4	-1	1	2.6	6.8	4.2					
	1.1	2	1.2	1.2	1.7	1.5					
	1.1	1.9	1.4	-1.7	-1.2	-1.1					
	-1.6	1.2	1.2	1.6	2.6	2.8					
	1.5	1.8	1.6	1.5	-1	1.4					
	1.3	1	-1.1	-1.1	-1.7	-1.7					
	-1.3	1	-1.1	1.8	2.3	2.7					
	-1.3	1.1	-1.3	1.1	1.8	1.9					
	-1.7	1.1	-1	2.9	4.3	2.4					

TABLE 2 (Page 5)

Low		G3									
T1		T1		normal		normal		normal			
TC19A_BDE_DIFF		TC20A_BDE_DIFF		TC21A_BDE_DIFF		TC22A_BDE_DIFF		TC23A_BDE_DIFF			
1.9		1.5		1		1		1.7			
2		1.2		1.2		1		1.9			
-1.1		-1.1		-2		1		-1			
2.5		1.1		-1.1		1		1.8			
2.3		-1.3		-1.2		1		1.1			
2.6		2.3		-1.4		1		1.5			
1.2		1		1.6		1		1.5			
2.1		2.1		-1.4		1		1.4			
-1.3		-1.2		1.2		1		1.1			
1.2		1.3		1.3		1		1.2			
1.6		1.1		1		1		1.2			
1.9		1.9		-1.1		1		1.4			
1.5		-1		1.1		1		1.2			
-1.5		-1.4		-1.4		1		-1.2			
1.7		1.3		-1		1		1.3			
-1.2		-1.1		1.4		1		1.4			
-1.2		-1.1		1.5		1		-1.2			
1.6		2.4		-1.4		1		-1.1			
2.1		1.8		-1.6		1		1			
2		2.3		-1.5		1		1.3			

TABLE 2 (Page 6)

	Low						High			
normal	T1		G3	T1+TIS		T1		G3		
TC24A_BDE_DIFF	TC25A		TC28A_BDE_DIFF			TC29A_BDE_DIFF		TC30A_BDE_DIFF		
-1.1	2.9		2.1			2		1.9		
1.4	2		1.3			-1.1		3.2		
-1	-1.1		3.4			2.9		2.7		
-1.1	3.2		-1.4			2.5		2.3		
2	1.3		-1			2.1		3		
-1.8	3.8		-1.2			2.2		1.1		
2.2	1.1		1.6			12		3		
-1.6	2.4		-1.2			1.7		1.8		
1.4	-1.3		1			7.1		2.3		
1.6	1.5		1.4			2.5		2.3		
-1.1	2.2		3.5			2		1.8		
-1.3	2.3		-1.1			1.5		1.8		
1.2	1.9		1.6			2.8		4.1		
1.4	-1.3		2.1			1.8		2.4		
-1.1	2.3		1.9			1.5		1.9		
1.6	-1.2		1.1			-1		3		
1.5	-2		3.6			2.2		2.4		
-1.4	1.4		3.5			1.9		1.5		
-1.4	1.6		1.5			1.3		2.2		
-1.9	3.2		-1.3			1.6		-1.2		

TABLE 2 (Page 7)

G1/2		G2		G2		INV			
Ta		Ta/T1		Ta				normal	
TC31A_BDE_DIFF	1	TC32A_BDE_DIFF	4.4	TC33A_BDE_DIFF	2.5	TC34A_BDE_DIFF	2.3	TC35A_BDE_DIFF	2.3
1.1		9.1		-1.6		1.5		1.9	
3.1		5.5		3.7		3.2		2.3	
2.7		3.5		2		1.4		-3.6	
2		2		-2.2		1.1		1.2	
2.2		2.3		1.7		2.4		-1.6	
4.2		2.5		-1.5		9.8		1.1	
1.4		3.9		1.8		3		1.2	
3.2		2.4		-1.2		6.1		1.2	
6.1		3.8		1.5		2.1		1.4	
2.4		2.7		2.4		1.9		1.8	
1.4		3.7		1.7		2.8		1	
5.5		2		2.4		2.2		3.1	
2.3		3.5		2		1.9		1.7	
-1.4		3.2		2		2		1.9	
12		2.2		3.4		1.3		1.5	
3.2		4.4		3.5		2.2		3.2	
2.2		2.3		2.2		1.8		1.7	
2.4		1.3		1.4		1.6		1.8	
1.7		1.6		1.2		1.9		-1.7	

TABLE 2 (Page 8)

				Low		G2/3	
normal		normal		Ta		T1	
TC36A_BDE_DIFF		TC37A_BDE_DIFF		TC38A_BDE_DIFF		TC39A_BDE_DIFF	TC40A_BDE_DIFF
1.3		1.9		1.3		2.3	1.9
1.2		1.7		1.1		3	3.7
2.5		1.8		2.9		2.8	3.7
-1.2		-2.3		-1.6		2.4	3.2
-1.2		1.3		-1.2		6.8	1.3
-1.2		-2		-1.1		2.6	1.1
1.2		1.2		-1.1		6	4.3
1.1		-1.3		-1		3	2.1
1.5		1.2		1.2		4.7	4.5
1.6		1.7		1.4		2.2	1.3
-1.4		-1.9		1		1.3	1.6
1.1		-1.1		-1.1		3.1	2
1.9		1.8		1.6		2.5	1.6
1.8		1.7		1.6		3	2.9
1.3		1.6		1		1.7	1.6
1.3		1.9		1.3		2.6	1.9
-1.1		1		1.1		1.6	2.7
-1.3		-1.7		-1		1.4	1.6
1.3		2.3		1.2		3.3	2.8
-1.4		-2.1		-1.4		1.9	-1

TABLE 2 (Page 9)

G2		G2		G2		G2			
Ta		Ta		T1		Ta		INV	
TC41A_BDE_DIFF		TC42A_BDE_DIFF		TC43A_BDE_DIFF		TC44A_BDE_DIFF		TC45A_BDE_DIFF	
1.9		2.1		2.3		2.3		2.4	
2.4		2.2		4.6		3.5		1.2	
3.7		3.3		3.4		3.6		3.4	
1.2		2.1		1.9		3.2		-1.8	
1		2.3		5		2		1.1	
1.9		1.9		1.2		3.2		1.3	
1.5		1.3		7		11		1.3	
1.5		1.4		1.7		3.1		1.2	
-1.1		1.1		4.7		6.7		1.1	
2.6		2.2		2.7		2		1.7	
2.3		1.6		1.9		2.8		1.2	
1.5		1.6		1.8		2.5		1.2	
1.7		2.1		2		2.1		2	
2.6		2.1		2.4		2.8		1.5	
1.4		1.6		1.6		2		2	
3.1		1.4		2.6		2.8		1.3	
3.1		2.3		1.6		1.4		2	
2.1		1.6		1.8		2.9		1.2	
2.5		1.9		1.4		2.3		1.6	
1.5		1.3		1		2.6		1.3	

TABLE 2 (Page 10)

	normal		normal		normal			
	TC46A_BDE_DIFF		TC47A_BDE_DIFF		TC48A_BDE_DIFF		secrtd	
	1		1		-1.1		-1.8	
	-1.2		1		-1.1			
	1.7		1		3.6		1.1	
	-1.4		1		-1.1		-1.2	
	-1.2		1		1.1			
	1		1		-1.3		-1.6	
	-1		1		1.1		1.3	
	1.1		1		-1.2		-1.9	
	1.1		1		-1		1.9	
	1		1		1.1		-2.2	
	-1		1		-1.2		-2.2	
	-1.2		1		-1.3		-1.6	
	1		1		1.1		-1.2	
	1.1		1		1.4			
	1		1		-1.3		-1.9	
	-1.1		1		-1			
	1		1		1.1		3.6	
	1		1		-1.2		-2.3	
	-1.1		1		-1.5			
	-1.1		1		-1.3		-1.8	

Please renumber pages 89 to 104 of the specification as pages 106 to 121.

REMARKS

In a March 2, 2005 telephone conference between Examiner Johannsen and Daniel N. Smith of the undersigned's office, Examiner Johannsen requested certain amendments to the specification of the above-identified application. Specifically, Examiner Johannsen requested that pages 56 to 58 of the specification be submitted as figures and that the tables on pages 83 to 88 be replaced with more legible versions.

In response, applicants attach hereto as **Exhibit A** six (6) sheets of new Figures 1-6.

Further, applicants have amended the specification to include a Brief Description of Figures section with a description of each of the figures; have deleted pages 56 to 58; and have amended pages 55 and 59 to refer to Figures 1-6. Applicants maintain that the above amendments do not create any issue of new matter and are supported, *inter alia*, on pages 55 to 59 of the application as filed.

Applicants have also amended the specification to include larger replacement tables for the tables on pages 83 to 88. Applicants maintain that these amendments also do not create any issue of new matter and are supported, *inter alia*, on pages 83 to 88 of the application as filed.

In conclusion, based on the preceding amendments to specification requested by the Examiner and the remarks, applicants respectfully request prompt issuance of the subject application for which the issue fee was paid on December 15, 2004.

If a telephone interview would be of assistance in advancing issuance of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number

provided below.

No fee is deemed necessary in connection with the filing of this Amendment. However, if any other fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John R. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400